A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

Trial Profile

A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Bipolar I disorders
  • Focus Adverse reactions; Registrational
  • Acronyms ATLAS
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 04 May 2017 Status changed from recruiting to completed.
    • 08 Oct 2015 Planned number of patients changed from 1000 to 755 as reported by ClinicalTrials.gov record.
    • 08 Oct 2015 Planned End Date changed from 1 Sep 2017 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top